Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)
NCT07050472 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2026-02-12
Summary
This is a retrospective, single-center study evaluating the effectiveness and safety of consolidative durvalumab after cCRT in LS-SCLC in real-world setting.
Conditions
- Small-cell Lung Cancer
Sponsors & Collaborators
-
Anhui Shi, MD
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-11
- Primary Completion
- 2025-08-12
- Completion
- 2025-08-12
Countries
- China
Study Locations
More Related Trials
-
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
NCT04255836 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT05617963 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
NCT03519971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
NCT04948411 ·Status: COMPLETED
-
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
NCT03694236 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
NCT05157542 ·Status: UNKNOWN ·Phase: PHASE1
-
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
NCT04314297 ·Status: UNKNOWN ·Phase: PHASE2
-
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
NCT04449861 ·Status: COMPLETED ·Phase: PHASE3
-
A Real-world Study of Durvalumab for Lung Cancer in China
NCT04672759 ·Status: UNKNOWN
-
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
NCT07249879 ·Status: RECRUITING ·Phase: PHASE1
-
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
NCT05267392 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC
NCT03995875 ·Status: COMPLETED
-
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
NCT04622228 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
NCT05245994 ·Status: UNKNOWN ·Phase: PHASE2
-
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
NCT07246304 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
NCT06375109 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895 ·Status: RECRUITING ·Phase: PHASE3
-
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
NCT05696782 ·Status: RECRUITING ·Phase: PHASE2
-
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
NCT06908070 ·Status: RECRUITING ·Phase: PHASE4
-
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
NCT06348797 ·Status: RECRUITING ·Phase: PHASE1
-
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT06249282 ·Status: RECRUITING ·Phase: PHASE1
-
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
NCT05761977 ·Status: UNKNOWN